

Appendix 4E

Final Report for the financial year ended 30 June 2024

Current Reporting Period: **30 June 2024**

Previous Reporting Period: **30 June 2023**

Results for Announcement to the Market

	12 months to 30 June 2024	12 months to 30 June 2023	% Change
	\$	\$	
Revenue from ordinary activities	-	-	0%
Loss from ordinary activities after tax attributable to members	(17,661,714)	(13,077,422)	35%
Net loss for the period attributable to members	(17,661,714)	(13,077,422)	35%

Brief Explanation of Results

Operational Report

During the reporting period, significant advances were made in support of the development of the Company's synthetic anti-infective programme. Some of the highlights for the year were as follows:

- RECCE® 327 (R327) added to the World Health Organization's list of Antibacterial Products in Clinical Development
- Total of A\$11.17m received in R&D Rebate Advance Payments
- Australian Government awarded AUD \$54,947,284 Advanced Overseas Finding across Recce Pharmaceuticals Pty Ltd infectious disease portfolio
- US Department of Defence grants funding for Burn Wound Programme of US\$2 million (approx. A\$3 million). Funding will accelerate the development and evaluation of R327G as a gel-based treatment to rapidly resolve burn wound infections and minimise the onset of bacteremia complications in a military setting
- Established a strategic opportunity in South-East Asia to accelerate clinical anti-infective portfolio including a signed Memorandum of Understanding (MoU) with leading Indonesian biomedical company PT Etana Biotechnologies
- Recce to continue strategic partnership with Murdoch Children's Research Institute following positive results for R327 against Gonorrhoea and Mycobacterium abscessus lung infections and Escherichia coli
- New Family 4 patent granted in Australia, Canada and Israel and Family 2 patent granted in China for RECCE® Anti-Infectives

Appendix 4E

Final Report for the financial year ended 30 June 2024

Brief Explanation of Results (Continued)

Clinical progress

- Phase I intravenous (I.V.) clinical trial of R327 in 80 human subjects - complete and independently verified results released
- Phase I/II UTI/Urosepsis Rapid Infusion trial complete & positive efficacy data reported from 25 subjects dosed across various infusion times
- Human Research Ethics Committee (HREC) approval received to commence a Phase II clinical trial assessing R327 as a topical, broad-spectrum gel applied to Acute bacterial skin and skin structure infections (ABSSSI)
- Reported positive results from patients with diabetic foot infections (DFI) treated with R327 under TGA Special Access Scheme – five (5) patients dosed with complex infections unable to be treated by existing antibiotics – surgery/amputation was averted and wound healing observed for all patients
- Positive Human Efficacy Data from Phase I/II trial evaluating R327 Gel in patients with DFIs and expanded trial to additional domestic and international sites

Financial Report

The operating loss has increased to \$17,661,714 (2023: loss of \$13,077,422) as a result of increased expenditure in consulting and research and development costs. The annual loss was after a R&D tax incentive of \$4,906,010 (2023: \$4,311,202).

The loss per share has increased during the year to 9.97 cents (2023: 7.52 cents).

The Group's focus is on progressing RECCE® 327 into human clinical trials.

Dividends

	Amount per Security	Percentage Franked
Final Dividend	Nil	N/A
Interim Dividend	Nil	N/A
Date the Dividend is Payable:	N/A	N/A
Record Date for determining entitlements to the Dividends:	N/A	N/A

The Company did not declare a dividend during the financial year and has not declared a dividend since the end of the financial year.

Net Tangible Assets per Security

As at 30 June 2024 (cents)	(4.67)
As at 30 June 2023 (cents)	(1.45)

This announcement has been approved for release by Recce Pharmaceuticals Board.